Nebivolol Krka (Nebivolol)

Nebivolol is a selective β1‑blocker used in cardiovascular conditions that require blood‑pressure reduction or improved cardiac function.

• Hypertension: lowers systolic and diastolic blood pressure, reducing risk of stroke and myocardial infarction.
• Heart failure: enhances cardiac output and alleviates symptoms of chronic heart failure.
• Hypertension in chronic kidney disease: provides effective blood‑pressure control while preserving renal function.

• Nebivolol selectively antagonizes β1‑adrenergic receptors, decreasing heart rate and myocardial contractility, which reduces cardiac output and peripheral resistance. In addition, it stimulates endothelial nitric‑oxide synthase, increasing nitric‑oxide release and causing vasodilation, further lowering systemic vascular resistance and blood pressure.

Nebivolol may cause a range of adverse reactions, from mild to serious.

Common Side Effects

• Headache: mild to moderate intensity.
• Dizziness or light‑headedness, especially on standing.
• Fatigue or tiredness.
• Nausea or abdominal discomfort.
• Bradycardia: heart rate below 60 bpm.
• Peripheral edema: mild swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Symptomatic hypotension with fainting.
• Bronchospasm or worsening asthma.
• Acute heart failure decompensation.
• Allergic reactions such as rash, angioedema, or anaphylaxis.

Before initiating Nebivolol, clinicians should consider several safety measures.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Heart rate monitoring: watch for bradycardia, especially in patients on other rate‑lowering agents.
• Respiratory caution: avoid in patients with severe asthma or chronic obstructive pulmonary disease.
• Hepatic impairment: dose adjustment may be required in moderate to severe liver disease.
• Discontinuation: taper gradually to prevent rebound hypertension or tachycardia.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other β‑blockers: additive bradycardia and hypotension.
• Non‑dihydropyridine calcium‑channel blockers (verapamil, diltiazem): may cause severe bradycardia.
• Strong CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): increase nebivolol plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effect.
• ACE inhibitors or ARBs: enhanced blood‑pressure lowering.
• NSAIDs: may blunt antihypertensive response.
• Antiarrhythmic agents (e.g., amiodarone): possible conduction disturbances.